UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Public ClinicalTrials.gov record NCT02722668. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen
Study identification
- NCT ID
- NCT02722668
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Enrollment
- 15 participants
Conditions and interventions
Conditions
- Acute Leukemia
- Acute Lymphoblastic Leukemia/Lymphoma
- Acute Myeloid Leukemia
- Biphenotypic/Undifferentiated/Prolymphocytic Leukemias
- Bone Marrow Failure Syndromes
- Burkitt's Lymphoma
- Chronic Myelogenous Leukemia
- Follicular Lymphoma
- Hodgkin Lymphoma
- Large-cell Lymphoma
- Leukemia or MDS in Aplasia
- Lymphoplasmacytic Lymphoma
- MRD Positive Leukemia
- Mantle-cell Lymphoma
- Marginal Zone B-cell Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasms/Myelofibrosis
- Natural Killer Cell Malignancies
- Plasma Cell Leukemia
- Prolymphocytic Leukemia
- Relapsed Chronic Lymphocytic Leukemia
- Relapsed Multiple Myeloma
- Relapsed Small Lymphocytic Lymphoma
- Relapsed T-Cell Lymphoma
Interventions
- ATG Biological
- Cyclophosphamide Drug
- Fludarabine Drug
- MMF Drug
- Sirolimus Drug
- TBI Radiation
- Umbilical cord blood cell infusion Biological
Biological · Drug · Radiation
Eligibility (public fields only)
- Age range
- Up to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 14, 2017
- Primary completion
- Feb 21, 2023
- Completion
- Feb 21, 2024
- Last update posted
- Jul 3, 2025
2017 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Masonic Cancer Center at University of Minnesota | Minneapolis | Minnesota | 55455 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02722668, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 3, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02722668 live on ClinicalTrials.gov.